Les corticostéroïdes inhalés versus bêta2-agonistes à action prolongée dans la maladie pulmonaire obstructive chronique https://t.co/5DLO4ZwRUL
Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.: CONCLUSI... http://t.co/65bjWWkT
Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.: CONCLUSI... http://t.co/fZMKJw4M
RT @FUNDACIONLIBRA: LABA and ICS in COPD confer similar benefits, including the frequency of exacerbations and mortality. Cochrane http://t.co/qrcx0VPY
RT @FUNDACIONLIBRA: LABA and ICS in COPD confer similar benefits, including the frequency of exacerbations and mortality. Cochrane http://t.co/qrcx0VPY
LABA and ICS in COPD confer similar benefits, including the frequency of exacerbations and mortality. Cochrane http://t.co/B8JDqkPJ
LABA and ICS in COPD confer similar benefits, including the frequency of exacerbations and mortality. Cochrane http://t.co/qrcx0VPY
LABA and ICS in COPD confer similar benefits, including the frequency of exacerbations and mortality. Cochrane http://t.co/WpybS0J5
Comparing inhaled corticosteroids with long-acting beta2-agonists in treating #COPD. http://t.co/ICpm3AFn”
Comparing inhaled corticosteroids with long-acting beta2-agonists in treating #COPD. http://t.co/U4yfiCAT